Abstract
Background The SARS-Cov2 virus binds to the ACE2 receptor for cell entry. It has been suggested that ACE-inhibitors, which are commonly used in patients with hypertension or diabetes and which raise ACE2 levels, may increase the risk of severe COVID-19 infection.
Methods We evaluated this hypothesis in an early cohort of 205 acute inpatients with COVID-19 at King’s College Hospital and Princess Royal University Hospital, London, UK with the primary endpoint being death or transfer to a critical care unit for organ support within 7-days of symptom onset.
Findings 53 patients out of 205 patients reached the primary endpoint. Contrary to the hypothesis, treatment with ACE-inhibitors was associated with a reduced risk of rapidly deteriorating severe disease. There was a lower rate of death or transfer to a critical care unit within 7 days in patients on an ACE-inhibitor OR 0.29 (CI 0.10-0.75, p<0.01), adjusting for age, gender, comorbidities (hypertension, diabetes mellitus, ischaemic heart disease and heart failure).
Interpretation Although a small sample size, we do not see evidence for ACE-inhibitors increasing the short-term severity of COVID-19 disease and patients on treatment with ACE-inhibitors should continue these drugs during their COVID-19 illness. A potential beneficial effect needs to be explored as more data becomes available.
Competing Interest Statement
JTHT received research support and funding from InnovateUK, Bristol-Myers-Squibb, iRhythm Technologies, and holds shares <£5,000 in Glaxo Smithkline and Biogen.
Funding Statement
DMB is funded by a UKRI Innovation Fellowship as part of Health Data Research UK MR/S00310X/1 (https://www.hdruk.ac.uk). RB is funded in part by grant MR/R016372/1 for the King’s College London MRC Skills Development Fellowship programme funded by the UK Medical Research Council (MRC, https://mrc.ukri.org) and by grant IS-BRC-1215-20018 for the National Institute for Health Research (NIHR, https://www.nihr.ac.uk) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. AF is supported by grant IS-BRC-1215-20018 for the National Institute for Health Research (NIHR, https://www.nihr.ac.uk) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London and The National Institute for Health Research University College London Hospitals Biomedical Research Centre. RJBD is supported by: 1. Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. 2. The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA; it is chaired by DE Grobbee and SD Anker, partnering with 20 academic and industry partners and ESC. 3. The National Institute for Health Research University College London Hospitals Biomedical Research Centre. 4. National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. KO’G is supported by an MRC Clinical Training Fellowship. RZ is supported by a King’s Prize Fellowship. AS is supported by a King’s Medical Research Trust studentship. AMS is supported by the British Heart Foundation (CH/1999001/11735), the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s & St Thomas’ NHS Foundation Trust and King’s College London (IS-BRC-1215-20006), and the Fondation Leducq. AP is partially supported by NIHR NF-SI-0617-10120. This work was supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC) Clinical and Research Informatics Unit (CRIU), NIHR Health Informatics Collaborative (HIC), and by awards establishing the Institute of Health Informatics at University College London (UCL). This work was also supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust. This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would also like to thank all the clinicians managing the patients, the patient experts of the KERRI committee, Professor Irene Higginson, Professor Alastair Baker, Professor Jules Wendon, Dan Persson and Damian Lewsley for their support.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint author
Data Availability
Source text from patient records used in the study will not be available due to inability to fully anonymise up to the Information Commissioner Office (ICO) standards and would be likely to contain strong identifiers (e.g. names, postcodes) and highly sensitive data (e.g. diagnoses). A subset of the dataset limited to anonymisable information (e.g. only UMLS codes and demographics) is available on request to researchers with suitable training in information governance and human confidentiality protocols subject to approval by the King’s College Hospital Information Governance committee;